Very Low-Dose Oral Immunotherapy Shows Promise for Children with Multiple Food Allergies

Two groundbreaking studies have demonstrated that very low-dose oral immunotherapy (VLOIT) can effectively treat children with food allergies while significantly reducing treatment-related risks compared to standard high-dose protocols. The research offers new hope for safer, more accessible treatment options for the estimated 30% of allergic children who react to multiple foods.

Multi-Nut Therapy Breakthrough

An open-label clinical trial involving 18 children with confirmed allergies to between two and five nuts showed remarkable efficacy using maintenance doses of just 30mg protein per nut. The study, published in Clinical and Translational Allergy, enrolled children with oral food challenge-confirmed reactions to each nut at doses of 444mg protein or less, with a median age of 5 years at enrollment.

Participants began daily treatment with a mixed nut preparation containing just 4mg protein per nut, with doses escalated every two months until reaching the 30mg maintenance dose. After 18 months of therapy, the median tolerated dose increased dramatically from 10mg protein per nut at baseline to 1000mg at the exit oral food challenge - a statistically significant improvement.

"Two-thirds of participants tolerated the maximum challenge dose of 2040mg protein per nut," according to the study results. In an intention-to-treat analysis, 14 of 18 children met predefined efficacy criteria, defined as tolerating at least five times their baseline dose or a minimum of 300mg protein.

Safety Profile Advantages

The safety profile proved particularly encouraging across both studies. In the multi-nut trial, no participants required treatment with epinephrine during the entire study period, addressing a key concern associated with higher-dose protocols.

A separate randomized controlled trial published in the Journal of Allergy and Clinical Immunology - In Practice compared low-dose and standard-dose peanut oral immunotherapy in 51 children. The study randomly assigned participants to three groups: low-dose treatment (30mg maintenance), standard-dose treatment (300mg maintenance), or avoidance.

"Children who were in the 30mg maintenance group had fewer adverse reactions than the 300mg maintenance group, and none withdrew from treatment," reported Dr. Julia Upton, Head of the Division of Immunology & Allergy at SickKids and co-first author of the peanut study.

Comparable Efficacy at Lower Doses

Both peanut oral immunotherapy treatment groups experienced significant and similar increases in their allergic reaction threshold, demonstrating that small amounts can be as effective as larger doses for immune system training.

"We were excited to find that peanut OIT maintenance doses can be much lower than previously thought and still contribute to positive outcomes," says Dr. Upton. "The more options we have, the more we can support patients' experience and provide meaningful, tailored care."

Dr. Thomas Eiwegger, Adjunct Scientist in the Translational Medicine program and co-senior study author, noted the practical benefits: "This is a small enough dose that even children who do not like the taste can continue treatment. This is the first time we've compared standard doses to such a low dose, but the minimum maintenance dose to provide benefit may be even lower than 30mg."

Clinical Implications

The research addresses significant challenges with current oral immunotherapy approaches, which typically require relatively high maintenance doses of 300mg protein or more and are usually delivered for one allergen at a time. Higher doses are associated with increased adverse effects, creating barriers to treatment adoption.

In Canada, peanut allergies affect almost two percent of children and adults and increasingly contribute to hospital admissions. Current peanut oral immunotherapy approaches using large doses require lengthy treatment, close medical supervision, and often result in discontinuation due to taste issues and side effects including anaphylaxis.

"The study found that very small amounts of peanuts, that are associated with less reactions, could be used as effectively as large amounts for oral immunotherapy, making it safer and accessible to more Canadians, even those who are very sensitive to the allergen," explains Dr. Moshe Ben-Shoshan, co-senior author and pediatric allergy specialist at Montreal Children's Hospital.

Future Treatment Strategies

The research teams note that treatment approaches can be individualized based on patient and family preferences. Some children and families may choose to remain on very low doses, while others may prefer to increase over time depending on their goals.

If confirmed in larger, controlled studies, the very low-dose approach could represent an important advance for children with complex, multi-food allergies and support broader adoption of safer, personalized immunotherapy strategies in pediatric allergy care. The findings suggest that oral immunotherapy could become accessible to more children with food allergies by reducing treatment-related risks while maintaining therapeutic efficacy.